What's in Chang, Steve S., M.D.'s pipeline?

Chang, Steve S., M.D. has 2 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 1 in Phase 1.

Which companies overlap with Chang, Steve S., M.D.'s portfolio?

Top competitors by shared drug class: Assistance Publique Hopitaux De Marseille.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/chang-steve-s-m-d.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Chang, Steve S., M.D. — Portfolio Competitive Intelligence Brief

Chang, Steve S., M.D. pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
DDAVP	DDAVP	marketed	Vasopressin receptor agonist	V2 vasopressin receptor (AVPR2)	Endocrinology, Hematology

Therapeutic area mix

Endocrinology, Hematology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Assistance Publique Hopitaux De Marseille · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Chang, Steve S., M.D.:

Cite this brief

Drug Landscape (2026). Chang, Steve S., M.D. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/chang-steve-s-m-d. Accessed 2026-05-16.